Last reviewed · How we verify

NCT03688906

AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

Completed Last updated 2 March 2022
What this trial tests

trial in Colo-rectal Cancer in 3,275 participants. Completed in 25 November 2019.

Timeline
12 January 2018
Primary endpoint
25 November 2019
25 November 2019

Quick facts

Lead sponsorFreenome Holdings Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3,275
Start date12 January 2018
Primary completion25 November 2019
Estimated completion25 November 2019
Sites30 locations across Canada, United States

Conditions studied

Sponsor

Freenome Holdings Inc.

Who can join

18 and older, any sex, with Colo-rectal Cancer or Cancer Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Cell-free DNA analysis in current cancer clinical trials: a review.
    Cisneros-Villanueva M, Hidalgo-Pérez L, Rios-Romero M, Cedro-Tanda A, et al · · 2022 · cited 137× · PMID 35027672 · DOI 10.1038/s41416-021-01696-0
  2. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA.
    Wan N, Weinberg D, Liu TY, Niehaus K, et al · · 2019 · cited 136× · PMID 31443703 · DOI 10.1186/s12885-019-6003-8
  3. Artificial Intelligence and Cardiovascular Genetics.
    Krittanawong C, Johnson KW, Choi E, Kaplin S, et al · · 2022 · cited 27× · PMID 35207566 · DOI 10.3390/life12020279
  4. Liquid Biopsies: Emerging role and clinical applications in solid tumours.
    Sisodiya S, Kasherwal V, Khan A, Roy B, et al · · 2023 · cited 21× · PMID 37327582 · DOI 10.1016/j.tranon.2023.101716
  5. Rise of Clinical Studies in the Field of Machine Learning: A Review of Data Registered in ClinicalTrials.gov.
    Zippel C, Bohnet-Joschko S. · · 2021 · cited 11× · PMID 34064827 · DOI 10.3390/ijerph18105072
  6. Liquid biopsies for colorectal cancer: a narrative review of ongoing clinical trials and the current use of this technology at a comprehensive cancer center.
    Broccard SP, Kasbi AA, Bagaria SP, Jones J, et al · · 2022 · cited 8× · PMID 35284120 · DOI 10.21037/jgo-21-470
  7. Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.
    Garcia-Pelaez J, Yáñez Y, Aupí M, Lázaro M, et al · · 2026 · PMID 42194957 · DOI 10.3390/genes17050500
  8. New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication.
    Rajput M, Pandey M, Dixit R. · · 2026 · PMID 41593642 · DOI 10.1186/s12957-025-04185-3

Verify or expand the search:

Other recruiting trials for Colo-rectal Cancer

Currently open trials in the same condition.

Other Freenome Holdings Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03688906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing